Pancreatic Cancer Drug Development Services
Our scientific innovation platform is driven by the expertise of our highly qualified team of scientists and is supported by state-of-the-art infrastructure as well as market-leading technology.
Pancreatic cancer (PC) is a recalcitrant and serious disease due to its complex and latent pathogenesis and the lack of early diagnostic methods. The mortality rate of PC is rapidly increasing and PC is expected to be the second most common of all malignant tumors by 2030.
We briefly describe the diagnostic strategies and the potential biomarkers for the early diagnosis of PC.
Drugs targeting the DNA damage-repair (DDR) pathway; targeting cancer metabolism; targeting tumor microenvironment; immunotherapy.
Global analysis of biological systems at the molecular level using high-throughput technologies has led to new advances in improving the diagnosis and treatment of PC.
PC clinical trials are research studies that offer promising new cancer treatments for patients that are not yet readily available.
Ease of structural modification, better suitability for clinical needs, and lower cost.
Less immunogenic, more stable ex vivo, higher activity, greater specificity and affinity, easier to synthesize and modify.
More effective and less toxic.
Safer properties and effective pharmacodynamics.
Showing potential as a new targeted therapeutic approach in PC treatment.
Alfa Cytology is a CRO company comprised of scientists, bioinformaticians, oncologists, and so on. Our team works closely and communicates actively to achieve our common goals of helping researchers and professionals understand PC biology, explore new PC therapeutics and protocols, and develop new PC biomarkers.